NIH UM1 Grants — Multi-Component Cooperative Agreement

Recent UM1 awards from NIH RePORTER

Examples of funded UM1 projects across the last two fiscal years. The matching-award count comes from the full result set; funding totals, averages, rankings, and examples use the first 500 records returned by NIH RePORTER. Figures reflect a snapshot last refreshed on September 5, 2026.

Example UM1 projects from the sample

• International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network

  3UM1AI106716-14S1
  Grace Aldrovandi · UNIVERSITY OF CALIFORNIA LOS ANGELES, CA · $536,039 · awarded Aug 28, 2026 · NIH

  ABSTRACT The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network has significantly advanced efforts to stem the global HIV epidemic among pregnant women, infants, children and adolescents through the conduct of high-quality clinical trials. The IMPAACT vision and overall goal is to end the worldwide HIV epidemic among these…

• Mouse Phenotyping Informatics Infrastructure - Data acquisition, integration, analysis and translation of high throughput mammalian phenotyping data.

  3UM1HG006370-15S1
  Helen Parkinson · EUROPEAN MOLECULAR BIOLOGY LABORATORY · $301,622 · awarded Aug 27, 2026 · NIH

  PROJECT SUMMARY The International Mouse Phenotyping Project (MPI2) is a critical resource for biomedical research providing novel gene-phenotype associations for genes with little or no known function, supplying strains for thousands of mechanistic studies and delivering integration with genomic, phenomic and human disease-relevant information providing…

• NUCATS CTSA UM1 at Northwestern University

  5UM1TR005121-03
  Richard D'Aquila · NORTHWESTERN UNIVERSITY, IL · $7,883,796 · awarded Aug 26, 2026 · NIH

  Over prior funding cycles, the Northwestern University Clinical and Translational Sciences (NUCATS) Institute has developed and delivered a robust institutional infrastructure to support clinical and translational research. Our mature CTSA hub has made exceptional contributions to the consortium, attaining national prominence for igniting cross-disciplinary…

• Immune Tolerance Network

  3UM1AI109565-13S1
  Jane Buckner · BENAROYA RESEARCH INST AT VIRGINIA MASON, WA · $427,401 · awarded Aug 25, 2026 · NIH

  Project summary / ABSTRACT The mission of the ITN is to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics based upon testable mechanistic hypotheses. The ITN is structured in order to interrogate different diseases across the immunologic spectrum, with integration of innovative clinical…

• REACH: Research Enterprise to Advance a Cure for HIV

  4UM1AI164565-06
  R. Brad Jones · WEILL MEDICAL COLL OF CORNELL UNIV, NY · $5,414,805 · awarded Aug 25, 2026 · NIH

  Modified Project Summary/Abstract Section Despite the success of standard antiretroviral therapy (ART), the need for an HIV cure remains compelling, both to improve the lives of PWH and to bring about the end of the pandemic. Strategies for an HIV cure fall under two categories: those that seek ART-free ‘remission’, and those targeting a classical cure or…

• PERU Clinical Trial Unit

  3UM1AI069438-20S4
  Jorge Sanchez · ASOCIACION CIVIL IMPACTA SALUD Y EDUCACN · $533,846 · awarded Aug 25, 2026 · NIH

  The overarching goal of the proposed renewal of the PERU CTU is to continue contributing to the design and implementation of the NIH HIV/AIDS clinical trial networks research agenda, across the continuum from prevention to treatment of HIV and tuberculosis (TB). It builds upon 25 years of experience and over $120 million of NIH investment to establish a…

• HOPE - HIV Obstruction by Programmed Epigenetics

  4UM1AI164559-06
  Melanie Ott · J. DAVID GLADSTONE INSTITUTES, CA · $4,870,431 · awarded Aug 21, 2026 · NIH

  PROJECT SUMMARY/ABSTACT After 40 years, an HIV cure remains elusive as latent reservoir cells persist despite antiretroviral therapy (ART), continually reigniting infection. The HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory proposes a novel “block-lock-stop” approach for durable proviral silencing and permanent viral control, aiming to…

• Reversing Immune Dysfunction for HIV-1 Eradication

  4UM1AI164561-06
  SUMIT CHANDA · SCRIPPS RESEARCH INSTITUTE, THE, CA · $4,958,401 · awarded Aug 20, 2026 · NIH

  PROJECT SUMMARY Although the rate of new HIV infections has decreased, containment and eventual eradication of the HIV pandemic remains a top priority in contemporary biomedical research. One of the major challenges to HIV cure is the need to restore normal immune function in order to effectively eliminate the established viral reservoir. We have assembled…

• Boston University Clinical and Translational Science Institute

  1UM1TR005308-01A1
  DAVID CENTER · BOSTON UNIVERSITY MEDICAL CAMPUS, MA · $5,801,798 · awarded Aug 19, 2026 · NIH

  The Boston University (BU) CTSI hub sits at the nexus of a research-intensive university, New England’s largest essential hospital system, and the Veterans Health Administration’s most prominent research system. Established in 2008, the hub is comprised of BU, partner Boston Medical Center Health System (with its 3 hospitals and 13 affiliated Community…

• University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit

  3UM1AI069423-20S3
  Joseph Eron · UNIV OF NORTH CAROLINA CHAPEL HILL, NC · $177,134 · awarded Aug 19, 2026 · NIH

  Abstract The University of North Carolina (UNC) Global HIV Prevention and Treatment Clinical Trials Unit (CTU) has a well-established record of high quality, innovative clinical research, strong network and scientific leadership. The CTU engages with critically important populations infected with and at high risk of HIV in southeastern US, southern Africa…

• BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

  4UM1AI164570-06
  Luis Montaner · WISTAR INSTITUTE, PA · $5,586,045 · awarded Aug 19, 2026 · NIH

  Summary Current HIV curative strategies have proven insufficient to eradicate viral reservoirs or prevent viral rebound after antiretroviral therapy (ART) cessation. The unifying hypothesis for the BEAT-HIV Collaboratory is that through a better mechanistic understanding of HIV latent reservoirs and host factors governing viral control and reactivation,…

• Collaboratory of AIDS Researchers for Eradication (CARE)

  4UM1AI164567-06
  DAVID MARGOLIS · UNIV OF NORTH CAROLINA CHAPEL HILL, NC · $5,318,544 · awarded Aug 18, 2026 · NIH

  Abstract Since its inception in 2011, the Martin Delaney Collaboratory program has made important advances towards a cure for HIV. In response to the Martin Delaney Collaboratories (MDC) for HIV Cure Research RFA, we seek to continue to advance the field by discovery of successful modalities to cure HIV infection. We will expand our expertise and work…

Compare nearby NIH grant mechanisms

Searchers often land on UM1 while deciding between adjacent NIH activity codes. Compare scope, NIH staff involvement, budget scale, and applicant stage before choosing a funding opportunity.